Bartel Frank, Taubert Helge, Harris Linda C
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Cancer Cell. 2002 Jul;2(1):9-15. doi: 10.1016/s1535-6108(02)00091-0.
MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Interestingly, more than 40 different splice variants of MDM2 transcripts have been identified both in tumors and normal tissues, and the majority of these variants do not contain sequence encoding the p53 binding site. This review describes the different splice forms, the tissues in which they have been identified, and their association with tumor progression and prognosis. In addition, we discuss the potential functions of these variants and how they interact with full-length MDM2 protein.
MDM2已被鉴定为一种与肿瘤抑制因子p53结合并促进其降解的蛋白质。有趣的是，在肿瘤组织和正常组织中均已鉴定出40多种不同的MDM2转录本剪接变体，其中大多数变体不包含编码p53结合位点的序列。本综述描述了不同的剪接形式、它们在哪些组织中被鉴定出来，以及它们与肿瘤进展和预后的关系。此外，我们还讨论了这些变体的潜在功能以及它们如何与全长MDM2蛋白相互作用。
